1229311-61-8

Basic information

• Product Name: 1-(TrifluoroMethyl)cyclopropanecarbaldehyde
• Synonyms: 1-(TrifluoroMethyl)cyclopropanecarbaldehyde;1-(trifluoromethyl)cyclopropane-1-carbaldehyde
• CAS NO: 1229311-61-8
• Molecular Formula: C₅H₅F₃O
• Molecular Weight: 138.0878096
• Mol File: 1229311-61-8.mol

Chemical Properties

• Boiling Point: 76.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.512±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(TrifluoroMethyl)cyclopropanecarbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(TrifluoroMethyl)cyclopropanecarbaldehyde(1229311-61-8)
• EPA Substance Registry System: 1-(TrifluoroMethyl)cyclopropanecarbaldehyde(1229311-61-8)

Safety Data

• Hazardous Substances Data: 1229311-61-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(TrifluoroMethyl)cyclopropanecarbaldehyde is used as an intermediate in the synthesis of various pharmaceuticals, leveraging its strong electron-withdrawing properties to facilitate the creation of complex molecular structures.
Used in Agrochemical Production:
TFMCH is utilized as an intermediate in the production of agrochemicals, where its reactivity and electron-withdrawing characteristics contribute to the development of effective compounds for agricultural applications.
Used in Organic Synthesis as a Reagent:
1-(TrifluoroMethyl)cyclopropanecarbaldehyde is used as a reagent in various synthetic processes within the field of organic chemistry. Its ability to introduce the trifluoromethyl group into organic molecules makes it a valuable tool for enhancing the properties of synthesized compounds.
Used in Research and Development:
TFMCH is employed in research and development settings to explore new synthetic pathways and investigate the properties of trifluoromethyl-containing compounds, further expanding the understanding and application of this unique chemical group.

Upstream product

• 371917-17-8 1-Hydroxymethyl-1-(trifluoromethyl)cyclopropane 
• 1011460-56-2 1-trifluoromethyl-cyclopropanecarboxylic acid methoxy-methyl amide 
• 277756-46-4 1-(trifluoromethyl)cyclopropanecarboxylic acid 

Relevant articles and documents

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmacetical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.